[an error occurred while processing this directive]
BBC News
watch One-Minute World News
Last Updated: Friday, 17 December, 2004, 18:55 GMT
AstraZeneca hit by drug failure
Pills
Two out of its three blockbuster drugs have been rejected
Shares in Anglo-Swedish drug have closed down 8% in UK trade after the failure of its Iressa drug in a major clinical trial.

The lung cancer drug did not significantly prolong survival in patients with the disease.

This setback for the group follows the rejection by the US in October of its anti-coagulant pill Exanta.

Meanwhile, another of its major money spinners - cholesterol drug Crestor - is facing mounting safety concerns.

"This would be two of the three blockbuster drugs that were meant to power the company forward failing... and we've got risks on Crestor," said Nick Turner, analyst at brokers Jefferies.

Rival pill

AstraZeneca had hoped to pitch its Iressa drug against rival medicine Tarceva.

But Iressa proved no better than a placebo in extending lives in the trial involving 1,692 patients.

Tarceva - made by OSI Pharmaceuticals, Genentech and Roche - has already proved to be successful in helping prolong the life of lung cancer patients.

AztraZeneca has now appointed a new executive director to the board.

John Patterson will be in charge of drug development.

The company said Mr Patterson would make "substantial changes to the clinical organisation and its processes".

"I am determined to improve our development and regulatory performance, restore confidence in the company and value to shareholders," said chief executive Tom McKillop.




SEE ALSO:
AstraZeneca hit by drug rejection
13 Sep 04 |  Business
New drugs fuelling AstraZeneca
22 Jul 04 |  Business
AstraZeneca in $355m fraud fine
20 Jun 03 |  Business
Drug giants beat forecasts
30 Apr 03 |  Business


RELATED INTERNET LINKS:
The BBC is not responsible for the content of external internet sites


PRODUCTS AND SERVICES

News Front Page | Africa | Americas | Asia-Pacific | Europe | Middle East | South Asia
UK | Business | Entertainment | Science/Nature | Technology | Health
Have Your Say | In Pictures | Week at a Glance | Country Profiles | In Depth | Programmes
Americas Africa Europe Middle East South Asia Asia Pacific